Overview
Description
The Colorado Adoption/Twin Study of Lifespan behavioral development & cognitive aging (CATSLife) aims are to: conduct a genetically sensitive study of individual differences in behavioral and cognitive change at the cusp of middle adulthood, in participants from the Colorado Adoption Project (CAP) and Longitudinal Twin Study (LTS) studied almost yearly from birth to early adulthood; map individual differences in growth and maintenance of cognitive abilities; evaluate and trace measured physical factors and health behaviors, biochemical markers and measured genetic pathways important to sustaining cognitive performance; and track measured environmental factors that might decrease, sustain or boost cognitive performance. (R01 AG046938 co-PI’s: Reynolds (contact), Wadsworth).
This data release includes from 1,062 respondents from the Longitudinal Twin Study (LTS) subsample who provided consent to share data and who completed cognitive assessments at one or more of the following assessments (early infancy (7 to 9 months), year 1-2 (14, 20, 24 months), year 3, year 7, year 16, or CATSLife wave 1 (mean year 29). All variables analyzed in the following paper are included [PMCID: PMC12130889], including polygenic scores for subjects who were genotyped.
Available Filesets
| Name | Accession | Latest Release | Description |
|---|---|---|---|
| CATSlife: Stability of Cognitive Ability | fsa000161 | NG00187 | Polygenic and Cognitive Assessment Scores |
View the File Manifest for a full list of files released in this dataset.
Data Dictionary Files
Participant Information
For a breakdown of the study population characteristics, navigate to the individual sample sets below.
| Sample Set | Accession Number | Number of Participants | Number of Samples |
|---|---|---|---|
| Stability of general cognitive ability from infancy to adulthood: A combined twin and genomic investigation | snd10136 | 1,062 | 1,062 |
Related Studies
-
The Colorado Adoption/Twin Study of Lifespan behavioral development & cognitive aging (CATSLife) aims are to: conduct a genetically sensitive study of individual differences in behavioral and cognitive change at the…
Cohorts
| Cohort | Number of Participants | Number of Samples |
|---|---|---|
| Colorado Adoption/Twin Study of Lifespan behavioral development & cognitive aging (CATSLife) | 1,062 | 1,062 |
Consent Levels
| Consent Level | Number of Participants | Number of Samples |
|---|---|---|
| HMB-IRB-PUB-NPU-MDS | 1,062 | 1,062 |
Visit the Data Use Limitations page for definitions of the consent levels above.
Acknowledgement
Acknowledgment statement for any data distributed by NIAGADS:
Data for this study were prepared, archived, and distributed by the National Institute on Aging Alzheimer's Disease Data Storage Site (NIAGADS) at the University of Pennsylvania (U24-AG041689), funded by the National Institute on Aging.
Use the study-specific acknowledgement statements below (as applicable):
For investigators using any data from this dataset:
Please cite/reference the use of NIAGADS data by including the accession NG00187.
For investigators using The Colorado Adoption/Twin Study of Lifespan behavioral development & cognitive aging (CATSLife) (sa000046) data:
The Colorado Adoption/Twin Study of Lifespan behavioral development & cognitive aging (CATSLife) project is supported by the National Institute on Aging (grant number NIA R01AG046938) and conducted at the University of Colorado Boulder.
Publications
- Gustavson DE. Stability of general cognitive ability from infancy to adulthood: A combined twin and genomic investigation. Proceedings of the National Academy of Sciences of the United States of America. 2025 May 27. PubMed link
Approved Users
- Investigator:Haines, JonathanInstitution:Case Western Reserve UniversityProject Title:Date of Initial Approval:October 30, 2026Current Status:ApprovedPublications:None ReportedResearch Use Statements:Show statementsTechnical Research Use Statement:Objectives: The overall goal of the planned analyses for ADAPTT is to better characterize the known genetic loci that are associated with AD/ADRD to identify the most probable functional elements responsible for the association. Most of these known associations have not been assigned to specific genes or functional variants. We plan to analyze DNA variation from SNP array, whole exome and whole genome sequence data generated from participants that span the spectrum of dementia (with a focus on Alzheimer disease (AD) but also including MCI and related dementias [ADRD]) and participants without dementia (typically considered “controls”). Study Design: We will evaluate these known loci, including the many genes underlying these associations, by integrating available genetic data, genomic data, in silico annotations, and multi-omic data using multiple different computational approaches. Our approaches will be sensitive to the different study designs of the contributing datasets (e.g. cohort studies, case-control studies, family-based studies). We will also examine a small number of these loci, prioritized by our analyses, using molecular genomic methods to better characterize the molecular mechanisms underlying the associations. Collaboration: This is a collaboration with Drs. Martin, Pericak-Vance, and Vance at the University of Miami.Non-Technical Research Use Statement:We are attempting to identify the inherited elements that contribute to Alzheimer disease risk. To do this we will analyze DNA sequence data from participants with Alzheimer disease and related dementias along with subjects who are cognitively normal. There are many known regions of the human genome that are associated with AD/ADRD risk, but the actual DNA sequence variations that are responsible for those associations remain unknown. Our goal is to use statistical and computer methods to identify the underlying responsible variations. For a small number of these, we will directly examine the biological mechanisms that help explain how those variations impact AD/ADRD.
- Investigator:Pan, WeiInstitution:University of MinnesotaProject Title:Date of Initial Approval:December 18, 2019Current Status:ApprovedPublications:Show publications (3)
- Knutson KA. MATS: a novel multi-ancestry transcriptome-wide association study to account for heterogeneity in the effects of cis-regulated gene expression on complex traits. Human molecular genetics. 2023 Apr 6. PubMed link
- He R. Enhancing nonlinear transcriptome- and proteome-wide association studies via trait imputation with applications to Alzheimer's disease. PLoS genetics. 2025 Apr. PubMed link
- Ren J. Large-Scale Genotype-Based Trait Imputation With Multi-Ancestry GWAS Data. Genetic epidemiology. 2026 Feb. PubMed link
Research Use Statements:Show statementsTechnical Research Use Statement:We have been developing more powerful statistical methods to detect common variant (CV)- or rare variant (RV)-complex trait associations and/or putative causal relationships for GWAS and DNA sequencing data. Here we propose applying our new methods, along with other suitable existing methods, to the existing ADSP sequencing data and other AD GWAS data provided by NIA, hence requesting approval for accessing the ADSP sequencing and other related GWAS/genetic data. We have the following two specific Aims: Aim1. Association testing under genetic heterogeneity: For complex traits, genetic heterogeneity, especially of RVs, is ubiquitous as well acknowledged in the literature, however there is barely any existing methodology to explicitly account for genetic heterogeneity in association analysis of RVs based on a single sample/cohort. We propose using secondary and other omic data, such as transcriptomic or metabolomic data, to stratify the given sample, then apply a weighted test to the resulting strata, explicitly accounting for genetic heterogeneity that causal RVs may be different (with varying effect sizes) across unknown and hidden subpopulations. Some preliminary analyses have confirmed power gains of the proposed approach over the standard analysis. Aim 2. Meta analysis of RV tests: Although it has been well appreciated that it is necessary to account for varying association effect sizes and directions in meta analysis of RVs for multi-ethnic cohorts, existing tests are not highly adaptive to varying association patterns across the cohorts and across the RVs, leading to power loss. We propose a highly adaptive test based on a family of SPU tests, which cover many existing meta-analysis tests as special cases. Our preliminary results demonstrated possibly substantial power gains. Aim 3. Inferring (putative) causal genes/proteins/metabolites for AD. We will apply TWA/PWAS/MWAS/xWAS methods to ADSP, AD GWAS and other omic data to identify (putative) causal genes, proteins, metabolites and other molecular traits for AD. These methods may be based on standard linear models or emerging ML/AI methods.Non-Technical Research Use Statement:We propose applying our newly developed statistical and computational methods, along with other suitable existing methods, to the existing ADSP sequencing data, other AD GWAS data and other omic data to detect common or rare genetic variants and other molecular traits, such as genes/proteins/metabolites, associated with and/pr (putative) causal to Alzheimer’s disease (AD). The novelty and power of our new methods are in three aspects: first, we consider and account for possible genetic heterogeneity with several subcategories of AD; second, we apply powerful meta-analysis methods to combine the association analyses across multiple subcategories of AD; third, we will develop and apply standard linear model- and emerging ML/AI-based causal inference methods to infer causal genes, proteins, metabolites and other traits for AD. In addition, our proposed analyses of the existing large amount of ADSP sequencing data and other AD GWAS data with our developed new methods are novel, powerful and cost-effective. - Investigator:Seshadri, SudhaInstitution:Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, University of Texas Health Sciences Center, San Antonio, TXDate of Initial Approval:October 14, 2020Current Status:ApprovedPublications:Show publications (9)
- Bouzid H. Clonal hematopoiesis is associated with protection from Alzheimer's disease. Nature medicine. 2023 Jul. PubMed link
- Horimoto ARVR. Admixture mapping implicates 13q33.3 as ancestry-of-origin locus for Alzheimer disease in Hispanic and Latino populations. HGG advances. 2023 Jul 13. PubMed link
- Tin A. Identification of circulating proteins associated with general cognitive function among middle-aged and older adults. Communications biology. 2023 Nov 3. PubMed link
- Wang Y. Key variants via the Alzheimer's Disease Sequencing Project whole genome sequence data. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2024 May. PubMed link
- Lee WP. Association of common and rare variants with Alzheimer's disease in more than 13,000 diverse individuals with whole-genome sequencing from the Alzheimer's Disease Sequencing Project. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2024 Dec. PubMed link
- Wang D. Frequency of variants in Mendelian Alzheimer's disease genes within the Alzheimer's Disease Sequencing Project. Journal of Alzheimer's disease : JAD. 2025 Apr. PubMed link
- Wang D. Application of the STAAR framework in detecting rare variant associations with Alzheimer disease and related dementias: Insights and implications. HGG advances. 2026 Apr 9. PubMed link
- Contreras AG. Genetic modifiers of APOE-ε4-associated cognitive decline. Nature communications. 2026 Feb 20. PubMed link
- Peloso GM. Whole genome sequencing analysis of over 3500 individuals dementia-free over 85 years old. Journal of Alzheimer's disease : JAD. 2026 Jun. PubMed link
Research Use Statements:Show statementsTechnical Research Use Statement:Objective: Utilize ADSP data sets to identify genes & specific genetic variants that confer risk for or protection from Alzheimer disease. Aim 1: Using combined WGS/WES across the ADSP Discovery, Disc-Ext, and FUS Phases, including single nucleotide variants, small insertion/deletions, and structural variants. We will: Aim 1a. Perform whole genome single variant and rare variant case/control association analyses of AD using ADSP and other available data; Aim 1b. Target protective variant identification via association analysis using selected controls within the ADSP data and performing meta analysis across association results based on selected controls from non-ADSP data sets. Aim 1c. Perform endophenotype analyses including cognitive function measures, hippocampal volume and circulation beta-amyloid ADSP data in subjects for which these measures are available. Meta analysis will be conducted across ADSP and non-ADSP analysis results. Aim 2: To leverage ethnically-diverse and admixed populations to identify AD variants we will: Aim 2a. Estimate and account for global and local ancestry in all analyses; Aim 2b. Perform admixture mapping in samples of admixed ancestry; and Aim 2c. Perform ethnicity-specific and trans-ethnic meta-analyses. Aim 3: To identify putative therapeutic targets through functional characterization of genes and networks via bioinformatics, integrative omics analyses. We will: Aim 3a. Annotate variants with their functional consequences using bioinformatic tools and publicly available “omics” data. Aim 3b. Prioritize results, group variants with shared function, and identify key genes functionally related to AD via weighted association analyses and network approaches. Analyses will be performed in coordination with the following PIs. Coordination will involve sharing expertise, analysis plans or analysis results. No individual level data will be shared across institutions. Philip De Jager, Columbia University; Eric Boerwinkle & Myriam Fornage, UT Health Science Center at Houston; Sudha Seshadri, UT Health Science Center at San Antonio; Ellen Wijsman, University of Washington; William Salerno, Baylor College of Medicine.Non-Technical Research Use Statement:This proposal seeks to analyze existing genetic sequencing data generated as part of the Alzheimer’s Disease Sequencing Project (ADSP) including the ADSP Follow-up Study (FUS) with the goal of identifying genes and specific changes within those genes that either confer risk for Alzheimer’s disease or provide protection from Alzheimer’s disease. Analytic challenges include analysis of whole genome sequencing data, appropriately accounting for population structure across European ancestry, Hispanic, and African American participants, and interpreting results in the context of other genomic data available. - Investigator:Zhao, DongjiaoInstitution:Messiah UniversityProject Title:Date of Initial Approval:June 26, 2026Current Status:ApprovedPublications:None ReportedResearch Use Statements:Show statementsTechnical Research Use Statement:This project will examine how genetic variants, gene expression profiles, transcriptomic patterns, APOE status where available, and biological pathways are associated with Alzheimer’s disease and related cognitive, functional, and neuropathological phenotypes. The goal is to identify genomic and pathway-level factors that may help explain cognitive decline, daily functional changes, neuropathological burden, and vulnerability or resilience in Alzheimer’s disease and related neurodegenerative or cognitive aging conditions. This study is a secondary analysis of existing coded/de-identified controlled-access data obtained through NIAGADS DSS. No new participants will be recruited, no participant contact will occur, and no new biospecimens or data will be collected. The requested datasets include Alzheimer’s disease sequencing data, oldest-old clinical and pathological data, microglia single-nuclei RNA-seq data, multi-brain-region mRNA-seq data from sporadic ALS, and genomic data related to cognitive ability. All analyses will comply with NIAGADS data use limitations, NIH Genomic Data Sharing Policy, NIA requirements, and Messiah University institutional oversight. Analyses will evaluate associations between genetic or gene-level features and approved phenotypes, including AD diagnosis, case-control status, cognitive performance, general cognitive ability, functional status, daily activity measures, neuropathological findings, microglia-related expression profiles, brain-region-specific expression patterns, and disease stage where available. Methods may include quality control, phenotype harmonization, regression-based association testing, differential gene expression analysis, variant-to-gene annotation, gene-level aggregation, pathway enrichment, and aggregate or polygenic measures if appropriate. Models will adjust for relevant covariates such as age, sex, ancestry, relatedness, brain region, cell type, disease stage, batch effects, and technical factors. Only aggregate or summary-level results will be reported.Non-Technical Research Use Statement:This project will use existing de-identified research data to study why some people develop Alzheimer’s disease or cognitive decline while others remain more resilient. The study will look at genetic information, gene activity, and biological pathways that may be related to memory, thinking ability, daily function, and brain changes seen in Alzheimer’s disease and related conditions. No new participants will be recruited, and no new samples will be collected. The project will only use approved research data from NIAGADS. The goal is to better understand how inherited genetic differences and changes in gene expression may contribute to Alzheimer’s disease, cognitive decline, and functional changes in daily life. This research may help identify biological patterns that could support future studies on earlier detection, risk prediction, and better understanding of neurodegenerative diseases. All data used in this project will be coded or de-identified. The study will not attempt to identify any individual participant, and results will only be reported in summary form.
- Investigator:Zhou, WeichenInstitution:University of MichiganProject Title:Date of Initial Approval:March 27, 2023Current Status:ApprovedPublications:Show publications (2)
- Zhou W. Somatic nuclear mitochondrial DNA insertions are prevalent in the human brain and accumulate over time in fibroblasts. PLoS biology. 2024 Aug. PubMed link
- Zhou W. A personalized multi-platform assessment of somatic mosaicism in the human frontal cortex. bioRxiv : the preprint server for biology. 2025 Oct 11. PubMed link
Research Use Statements:Show statementsTechnical Research Use Statement:Explore somatic transposable elements and their Alzheimer's disease-related patterns using genomic and phenotypic data from large cohorts: In order to explore the impact of the transposable element in Alzheimer's disease, we propose to conduct a systematic survey in the available large cohorts. The ADSP dataset in NIAGAlzheimer's diseaseS (Accession No. NG00067) includes 16,906 whole-genome sequences and 20,504 whole-exome sequences for case-control and family-based studies of Alzheimer's disease from diverse populations, which is a perfect resource to leverage in this project. Under the support of the Michigan Alzheimer's Disease Center, we will request to access NIAGADS. To detect somatic transposable elements in the ADSP dataset, we will employ established computational pipelines to resolve the transposable elements in the sequencing data, MELT and xTEA for WGS and SCRAMble for WES, respectively. Parameters in these tools, for instance, the calling threshold of supporting reads, will be adjusted accordingly to cooperate with the detection of somatic transposable elements in cells at low frequency. To exclude potential germline transposable elements, we will leverage a master set of polymorphic transposable elements from diverse populations, which are based on our previous projects at the Human Genome Structural Variation Consortium, and the case-control information provided by ADSP. We aim to summarize a spectrum of somatic transposable elements that would be Alzheimer's disease-relevant along with various clinical and phenotypic information. To build Alzheimer's disease-related genetic patterns we will implement Mutect2 (GATK) and Strelka2 to discover SNVs from WGS and WES data and link them with transposable elements in the same haplotype. After obtaining this set of patterns, we will collect phenotypic information from the ADSP dataset to conduct family-based associated analysis and gene-burden analysis. RegulomeDB will be used to annotate the effects of non-coding functional impact and regulatory changes for these Alzheimer's disease-related patterns.Non-Technical Research Use Statement:It seeks to explore the connection between the somatic transposable elements in the human genome and Alzheimer’s disease and related dementias. It will leverage large-scale datasets to extensively explore the genome-wide transposable elements and then stratify Alzheimer’s disease-relevant ones by using the rich clinical information from the cohorts. Further analysis pipelines will be built based on the results of the proposed project to investigate the functional impact of these transposable elements on Alzheimer’s disease and would improve the understanding of genetic causes of Alzheimer’s disease and related dementias.
Total number of participants: 1,062
| American Indian/Alaska Native | 9 |
| Asian | 2 |
| Native Hawaiian or Other Pacific Islander | 2 |
| Black or African American | 4 |
| White | 911 |
| Other | 52 |
| NA | 82 |
-
NA1,062 (100.0%)
| NA | ||
|---|---|---|
| Other | 1,062 | 100.0% |